U.S. pharma huge copyright scrapped two experimental weight loss capsules last calendar year—a after-daily tablet, lotiglipron, resulting from elevated liver enzymes along with a 2 times-daily pill, danuglipron, as a consequence of robust Uncomfortable side effects—but CEO Albert Bourla has explained the company is set to “play and win” fro